Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.

TitleSummary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.
Publication TypeJournal Article
Year of Publication2019
AuthorsHolstein, SA, J Ye, C, Howard, A, Bhutani, M, Gormley, N, Hahn, T, Hillengass, J, Krishnan, A, C Landgren, O, Munshi, NC, Oliva, S, Owen, RG, Pasquini, MC, Puig, N, Weinhold, N, Weisel, K, McCarthy, PL
JournalBiol Blood Marrow Transplant
Volume25
Issue3
Paginatione89-e97
Date Published2019 03
ISSN1523-6536
KeywordsBone Marrow Transplantation, Clinical Trials as Topic, Congresses as Topic, Education, Humans, Immunologic Factors, Multiple Myeloma, Neoplasm, Residual, Societies, Scientific
Abstract

The second annual Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling was convened on December 7, 2017, at the American Society of Hematology (ASH) meeting. During this workshop, investigators from around the world presented their latest research involving assessment of minimal residual disease (MRD) and immune profiling (IP) in myeloma. This document summarizes the workshop presentations as well as relevant ASH abstracts and focuses on the regulatory issues involved in the integration of MRD and IP assessment in clinical trial design and practice.
DOI10.1016/j.bbmt.2018.11.001
Alternate JournalBiol Blood Marrow Transplant
PubMed ID30408566
PubMed Central IDPMC6445685
Grant ListU10 HL069294 / HL / NHLBI NIH HHS / United States
UG1 HL069249 / HL / NHLBI NIH HHS / United States
U24 CA076518 / CA / NCI NIH HHS / United States
U24 HL138660 / HL / NHLBI NIH HHS / United States
UG1 HL069278 / HL / NHLBI NIH HHS / United States
P30 CA008748 / CA / NCI NIH HHS / United States
R01 HL107213 / HL / NHLBI NIH HHS / United States